Literature DB >> 20838770

Patient preferences for osteoporosis in Spain: a discrete choice experiment.

J Darbà1, G Restovic, L Kaskens, M A Balbona, A Carbonell, P Cavero, M Jordana, C Prieto, A Molina, I Padró.   

Abstract

UNLABELLED: In Spain, various treatments are available to prevent osteoporotic fractures. A discrete choice experiment (DCE) was used to investigate the importance of different treatment aspects and its influence on patients' preferences. All attributes included as type and place of drug administration as well as costs showed to be significant predictors of choice. Spanish osteoporosis patients have well-defined preferences and accept trade-offs among attributes.
INTRODUCTION: This study was designed to identify patient preferences for different aspects of osteoporosis treatments in Spain.
METHODS: Main attributes of severe osteoporosis treatments were determined by literature review and consultations with nurses. The discrete choice experiment included three attributes: type of drug administration, place of administration, plus a cost attribute in order to estimate willingness to pay for improvements in attribute levels. A pilot study with 50 patients was performed to identify the areas of misunderstanding. One hundred sixty-six patients with a diagnosis of osteoporosis and severe osteoporosis were presented with pairs of hypothetical treatment profiles with different type of administration levels, places of administration and costs. Questions to collect socio-demographic and disease-related treatment data were also included. Data were analysed using a random effects probit model.
RESULTS: All attributes had the expected polarity and were significant predictors of choice. Patients were willing to pay 183 euro/month to have a subcutaneous injection once per day rather than an intravenous injection once per year. Patients with osteoporosis were willing to pay 121 euro/month to have medical support when administering the drug treatment at home rather than being admitted several hours to a hospital for drug administration.
CONCLUSION: Spanish osteoporosis patients have well-defined preferences among treatment attributes and are willing to accept trade-offs among attributes. Participants indicated that they are willing to accept self medication with medical support rather than being hospitalised for several hours. The perspective of the patients should be taken into account when making treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838770     DOI: 10.1007/s00198-010-1382-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  11 in total

1.  Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation.

Authors:  M Ryan
Journal:  Soc Sci Med       Date:  1999-02       Impact factor: 4.634

2.  Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry.

Authors:  C Bouza; T López; M Palma; J M Amate
Journal:  Osteoporos Int       Date:  2007-01-13       Impact factor: 4.507

3.  Improving medication adherence through patient education distinguishing between appropriate and inappropriate utilization. Patient Education Study Group.

Authors:  S M Edworthy; G M Devins
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

4.  The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Authors:  Andrew Lloyd; Emma McIntosh; Martin Price
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

6.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

7.  Expanding patient involvement in care. Effects on patient outcomes.

Authors:  S Greenfield; S Kaplan; J E Ware
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

8.  Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment.

Authors:  Esther W de Bekker-Grob; Marie-Louise Essink-Bot; Willem Jan Meerding; Bart W Koes; Ewout W Steyerberg
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Doctor-patient communication in rheumatological disorders.

Authors:  L H Daltroy
Journal:  Baillieres Clin Rheumatol       Date:  1993-06

10.  Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.

Authors:  E W de Bekker-Grob; M L Essink-Bot; W J Meerding; H A P Pols; B W Koes; E W Steyerberg
Journal:  Osteoporos Int       Date:  2008-01-08       Impact factor: 4.507

View more
  14 in total

Review 1.  How important is mode of administration in treatments for rheumatic diseases and related conditions?

Authors:  Nick Bansback; Logan Trenaman; Mark Harrison
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

2.  Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.

Authors:  S Silverman; A Calderon; K Kaw; T B Childers; B A Stafford; W Brynildsen; A Focil; M Koenig; D T Gold
Journal:  Osteoporos Int       Date:  2012-12-18       Impact factor: 4.507

Review 3.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

4.  Incorporating patients' preferences into medical decision making.

Authors:  Liana Fraenkel
Journal:  Med Care Res Rev       Date:  2012-11-06       Impact factor: 3.929

5.  Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis.

Authors:  Mickael Hiligsmann; Caroline van Durme; Piet Geusens; Benedict Gc Dellaert; Carmen D Dirksen; Trudy van der Weijden; Jean-Yves Reginster; Annelies Boonen
Journal:  Patient Prefer Adherence       Date:  2013-02-07       Impact factor: 2.711

6.  Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain.

Authors:  Josep Darbà; Nuria Pérez-Álvarez; Lisette Kaskens; Susana Holgado-Pérez; Jill Racketa; Javier Rejas
Journal:  Clinicoecon Outcomes Res       Date:  2013-07-05

Review 7.  Health technology assessment in osteoporosis.

Authors:  Mickael Hiligsmann; John A Kanis; Juliet Compston; Cyrus Cooper; Bruno Flamion; Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Olivier Bruyere; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Journal:  Calcif Tissue Int       Date:  2013-03-21       Impact factor: 4.333

8.  The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes.

Authors:  Sieta T de Vries; Folgerdiena M de Vries; Thijs Dekker; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Adelita V Ranchor; Petra Denig
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 9.  A Review of Patient Preferences for Osteoporosis Drug Treatment.

Authors:  Mickaël Hiligsmann; Sandrine P G Bours; Annelies Boonen
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

Review 10.  A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.

Authors:  Colin H Ridyard; Dalia M M Dawoud; Lorna V Tuersley; Dyfrig A Hughes
Journal:  Patient       Date:  2016-08       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.